| 4.1 0.26 (6.77%) | 03-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.37 |
1-year : | 6.27 |
| Resists | First : | 4.59 |
Second : | 5.37 |
| Pivot price | 3.87 |
|||
| Supports | First : | 3.92 |
Second : | 3.51 |
| MAs | MA(5) : | 3.89 |
MA(20) : | 3.91  |
| MA(100) : | 3.71 |
MA(250) : | 2.65 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 49.9 |
D(3) : | 45.4 |
| RSI | RSI(14): 55.3 |
|||
| 52-week | High : | 6.59 | Low : | 1 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SABS ] has closed below upper band by 15.4%. Bollinger Bands are 15.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.44 - 4.46 | 4.46 - 4.48 |
| Low: | 3.96 - 3.97 | 3.97 - 3.99 |
| Close: | 4.07 - 4.1 | 4.1 - 4.13 |
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
Tue, 10 Mar 2026
SAB Biotherapeutics (NASDAQ:SABS) Price Target Cut to $7.00 by Analysts at HC Wainwright - MarketBeat
Tue, 10 Mar 2026
SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data - TipRanks
Tue, 10 Mar 2026
SAB Bio reports Phase 1 SAB-142 data showing C-peptide preservation signals in adult T1D cohort - TradingView
Tue, 10 Mar 2026
Early Type 1 diabetes trial of SAB-142 shows insulin marker signal - Stock Titan
Mon, 09 Mar 2026
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -20 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 4.761e+007 (%) |
| Held by Institutions | 1.912e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.033e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.56 |
| Profit Margin | 16 % |
| Operating Margin | 338.3 % |
| Return on Assets (ttm) | -37 % |
| Return on Equity (ttm) | 657.1 % |
| Qtrly Rev. Growth | 18.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -4.009e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -2.63 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 1.86e+006 |
| Forward Dividend | 1.56e+006 |
| Dividend Yield | 45365900% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|